Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Tanja Fens, Guiling Zhou, Maarten J. Postma, Eugène P. van Puijenbroek & Job F.M. van Boven. (2021) Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. Expert Opinion on Pharmacotherapy 22:7, pages 923-935.
Read now
Read now
Jesús Recio Iglesias, Francisco López García, Pere Almagro, José Manuel Varela Aguilar & Ramón Boixeda Viu. (2020) Spanish clinical practice consensus in internal medicine on chronic obstructive pulmonary disease patients with comorbidities (miEPOC). Current Medical Research and Opinion 36:6, pages 1033-1042.
Read now
Read now
Articles from other publishers (3)
Hélène Salvator, Emmanuel Naline, Marion Brollo, Hermann Tenor, Stanislas Grassin‐Delyle & Philippe Devillier. (2020) Clinical relevance of the relaxant effects of roflumilast on human bronchus: potentiation by a long‐acting beta‐2‐agonist. Fundamental & Clinical Pharmacology 35:4, pages 725-731.
Crossref
Crossref
Hélène Salvator, Amparo Buenestado, Marion Brollo, Emmanuel Naline, Tatiana Victoni, Elisabeth Longchamp, Hermann Tenor, Stanislas Grassin-Delyle & Philippe Devillier. (2020) Clinical Relevance of the Anti-inflammatory Effects of Roflumilast on Human Bronchus: Potentiation by a Long-Acting Beta-2-Agonist. Frontiers in Pharmacology 11.
Crossref
Crossref
Sadia Janjua, Rebecca Fortescue & Phillippa Poole. (2020) Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2020:5.
Crossref
Crossref